Inclusion Criteria (abbreviated):  Participants 18 to 60 years of age inclusive, at the time of signing the informed consent. Documented chronic HIV-1 infection on stable ART regimen Plasma HIV-1 levels below the limit of quantification Peripheral blood cluster of differentiation 4 (CD4) T cell count >500 cells/mm3 during screening Have previously been vaccinated for N. meningitidis with documented history and/or received a N. meningitidis vaccination prior to dosing Must be willing to use condoms throughout the duration of the study Willing to enroll into the Long-Term Follow-Up Study, EBT-101-002, for up to 15 years after receiving study drug  Exclusion Criteria (abbreviated):  Anti-AAV9 serum neutralizing antibodies >1:20 titer History of one or more HIV-related opportunistic infections within the past 2 years Documented prior HIV-1 drug resistance to ≥2 or more classes of ART defined as a single key mutations or an accumulation of minor mutations that result in resistance to entire respective drug classes within the past 5 years History of >1 change in ART due to virologic failure during preceding 2 years. Receiving or plans to receive long-acting injectable ART History of malignancy with the exception of successfully treated basal cell or squamous cell carcinoma of the skin